SGMO Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

40.25M

+433.04%

-0.013

-88%

20.55M

+219.25%

-0.063

-54.76%

21.50M

+17.45%

-0.063

-20.84%

Estimates Revision

The market is revising Downward the revenue expectations for Sangamo Therapeutics, Inc. (SGMO) for FY2025, with the revenue forecasts being adjusted by -9.49% over the past three months. During the same period, the stock price has changed by -40.05%.

Revenue Estimates for FY2025

Revise Downward

-9.49%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+14.98%

In Past 3 Month

Stock Price

Go Down

-40.05%

In Past 3 Month

3 Analyst Rating

Wall Street analysts forecast SGMO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SGMO is 4.33 USD with a low forecast of 1.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

2 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

1.00

Averages

4.33

High

10.00

Current: 0.000

Low

1.00

Averages

4.33

High

10.00

Barclays

Overweight -> Equal Weight

downgrade

$5 -> $1

2025-11-07

Reason

Barclays

Price Target

$5 -> $1

2025-11-07

downgrade

Overweight -> Equal Weight

Reason

Barclays downgraded Sangamo to Equal Weight from Overweight with a price target of $1, down from $5. The company's Q3 report highlighted the FDA's reaffirmation of an accelerated approval path using eGFR slope as the endpoint and its cash runway has been extended into Q1 of 2026, the analyst tells investors in a research note. Barclays steps to the sidelines pending further clarity on a Fabry deal.

Barclays

Overweight

downgrade

$9 -> $5

2025-05-14

Reason

Barclays

Price Target

$9 -> $5

2025-05-14

downgrade

Overweight

Reason

Barclays lowered the firm's price target on Sangamo to $5 from $9 and keeps an Overweight rating on the shares. The company's Q1 call provided additional color on cash runway extended into late Q3 by the capital raise, the analyst tells investors in a research note.

HC Wainwright & Co.

Patrick Trucchio

Strong Buy

Reiterates

$10

2025-04-07

Reason

HC Wainwright & Co.

Patrick Trucchio

Price Target

$10

2025-04-07

Reiterates

Strong Buy

Reason

RBC Capital

Luca Issi

Hold

Reiterates

2025-03-18

Reason

RBC Capital

Luca Issi

Price Target

2025-03-18

Reiterates

Hold

Reason

Truist Securities

Nicole Germino

Strong Buy

Maintains

$7 → $5

2025-01-23

Reason

Truist Securities

Nicole Germino

Price Target

$7 → $5

2025-01-23

Maintains

Strong Buy

Reason

Truist analyst Nicole Germino lowered the firm's price target on Sangamo to $5 from $7 and keeps a Buy rating on the shares. The firm is updating its model to reflect the return of a BLA-ready Phase 3 asset with competitive data in Hem A and pending more clarity on the longer-term cash position from a potentially near-term announcement of a partner for Phase 3 Fabry disease asset and additional capsid partnerships, the analyst tells investors in a research note. Truist adds that the longer-term cash runway for Sangamo hinges on a partner for Fabry, which may come with a meaningful upfront and royalties payments, removing the cash overhang.

Valuation Metrics

The current forward P/E ratio for Sangamo Therapeutics Inc (SGMO.O) is -2.19, compared to its 5-year average forward P/E of -4.15. For a more detailed relative valuation and DCF analysis to assess Sangamo Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-4.15

Current PE

-2.19

Overvalued PE

0.30

Undervalued PE

-8.60

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

1.26

Current EV/EBITDA

-1.98

Overvalued EV/EBITDA

27.45

Undervalued EV/EBITDA

-24.94

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

6.14

Current PS

1.41

Overvalued PS

10.85

Undervalued PS

1.43

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

SGMO News & Events

Events Timeline

No data

News

3.5

2025-12-18Globenewswire

Sangamo Initiates BLA Submission for ST-920, Expected in Q2 2026

8.5

2025-12-18Newsfilter

Sangamo Initiates BLA Submission for ST-920, Expected Completion in Q2 2026

9.0

2025-12-02Globenewswire

Sangamo Receives FDA Fast Track Designation for ST-503 in Chronic Pain Treatment

People Also Watch

Frequently Asked Questions

What is Sangamo Therapeutics Inc (SGMO) stock price today?

The current price of SGMO is 0.443 USD — it has decreased -1.55 % in the last trading day.

What is Sangamo Therapeutics Inc (SGMO)'s business?

Sangamo Therapeutics, Inc. is a genomic medicine company. The Company’s zinc finger (ZF) epigenetic regulators are ideally suited to potentially address neurological disorders and its capsid engineering platform has demonstrated the ability to expand delivery beyond available intrathecal delivery capsids, including in the central nervous system (CNS), in preclinical studies. Zinc finger technologies are derived from naturally occurring human proteins. They are composed of a DNA-binding domain, which binds with precision to any sequence of DNA, and various functional domains (such as nucleases and transcription factors) based on therapeutic needs. Its pipeline includes Chronic Neuropathic Pain - ST-503 and Isaralgagene civaparvovec (ST-920). ST-503 is an investigational epigenetic regulator for the treatment of intractable pain due to iSFN, a type of chronic neuropathic pain. ST-920 is a wholly owned gene therapy product candidate for the treatment of Fabry disease.

What is the price predicton of SGMO Stock?

What is Sangamo Therapeutics Inc (SGMO)'s revenue for the last quarter?

Sangamo Therapeutics Inc revenue for the last quarter amounts to 581.00K USD, decreased -98.82 % YoY.

What is Sangamo Therapeutics Inc (SGMO)'s earnings per share (EPS) for the last quarter?

Sangamo Therapeutics Inc. EPS for the last quarter amounts to -0.11 USD, decreased -375.00 % YoY.

What changes have occurred in the market's expectations for Sangamo Therapeutics Inc (SGMO)'s fundamentals?

How many employees does Sangamo Therapeutics Inc (SGMO). have?

Sangamo Therapeutics Inc (SGMO) has 183 emplpoyees as of January 10 2026.

What is Sangamo Therapeutics Inc (SGMO) market cap?

Today SGMO has the market capitalization of 149.07M USD.